Carmell Therapeutics Number Of Shares Shorted vs. EBITDA
| CTCX Stock | 0.30 0.02 7.14% |
For Carmell Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Carmell Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Carmell Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Carmell Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Carmell Therapeutics over time as well as its relative position and ranking within its peers.
Carmell |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carmell Therapeutics. If investors know Carmell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carmell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.48 | Revenue Per Share 0.001 | Return On Assets (0.85) | Return On Equity (1.76) |
The market value of Carmell Therapeutics is measured differently than its book value, which is the value of Carmell that is recorded on the company's balance sheet. Investors also form their own opinion of Carmell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carmell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carmell Therapeutics' market value can be influenced by many factors that don't directly affect Carmell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carmell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carmell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carmell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Carmell Therapeutics EBITDA vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Carmell Therapeutics's current stock value. Our valuation model uses many indicators to compare Carmell Therapeutics value to that of its competitors to determine the firm's financial worth. Carmell Therapeutics is rated second in number of shares shorted category among its peers. It is rated below average in ebitda category among its peers . Carmell Therapeutics reported EBITDA of (15.19 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Carmell Therapeutics' earnings, one of the primary drivers of an investment's value.Carmell EBITDA vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Carmell Therapeutics |
| = | 429.72 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Carmell Therapeutics |
| = | (15.19 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Carmell EBITDA Comparison
Carmell Therapeutics is currently under evaluation in ebitda category among its peers.
Carmell Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Carmell Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Carmell Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Carmell Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Carmell Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -28.3 M | -29.7 M | |
| Net Interest Income | -889.3 K | -933.8 K | |
| Operating Income | -5.2 M | -5.5 M | |
| Net Loss | -16.2 M | -17 M | |
| Income Before Tax | -16.2 M | -17 M | |
| Total Other Income Expense Net | -11 M | -10.4 M | |
| Net Loss | -15.4 M | -16.2 M | |
| Income Tax Expense | -760.2 K | -722.2 K | |
| Net Loss | (1.40) | (1.47) | |
| Income Quality | 0.54 | 0.30 | |
| Net Income Per E B T | 0.86 | 0.76 |
Carmell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Carmell Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Carmell Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Carmell Therapeutics' important profitability drivers and their relationship over time.
Use Carmell Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Carmell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Carmell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Carmell Therapeutics Pair Trading
Carmell Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Carmell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Carmell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Carmell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Carmell Therapeutics to buy it.
The correlation of Carmell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Carmell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Carmell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Carmell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Carmell Therapeutics position
In addition to having Carmell Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency ETFs Thematic Idea Now
Cryptocurrency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Cryptocurrency ETFs theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.